

5-6-02

W/d 1631
Box 500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Patent Examining Operations

#6/K.T.
5/9
I.D.

RECEIVED
MAY 07 2002
TECH CENTER 1600/2900

Applicant(s): Young et al
Parent Serial No: 09/873,367
Filed: 5 June 2001
Title: CANCER GENE DETERMINATION AND THERAPEUTIC SCREENING USING SIGNATURE GENE SETS
Docket No: 689290-64

Art Unit: Unassigned
Examiner: Unassigned

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

BOX SEQUENCE
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Prior Art Statement

Sir:

In addition to the enclosed Information Disclosure Statement and List of References (Form 1449), Applicant notes for the record that the claims of the above-referenced patent application relate to novel uses of the recited genes, gene sequences and expression products in assays for chemotherapeutic agents as well as in the diagnosis of cancer and the presence of cancer-related genes and proteins in cells and tissues. The nucleotide sequences themselves are not be claimed as inventive.

In an effort to assist the Examiner, Applicant encloses herewith on two diskettes copies of the gene sequences and their corresponding GenBank Accession Numbers as first disclosed in the provisional applications relied on for priority in the present application. These are as follows:

1. Diskette 1 – Filename = Colon-1.txt – sequences and accession numbers listed in Figure 1 of U.S. Provisional Application 60/209,531 (filed 5 June 2000) and 60/245,084 (filed 1 November 2000). There are 333 sequences (corresponding to SEQ ID NO: 1-333, respectively) contained in this listing, which represent genes found by Applicant to be expressed in normal cancer, here colon, cells but not appreciably or detectably expressed in colon adenocarcinoma cells.

2. Diskette 2 – Filename = Colon-2.txt – sequences and accession numbers listed in Figure 1 of U.S. Provisional Application 60/209,473 (filed 5 June 2000) and 60/244,867 (filed 1 November 2000). There are 189 sequences (corresponding to SEQ ID NO: 334-522, respectively) contained in this listing, which represent genes found by Applicant to be expressed in adenocarcinoma, here colon, cells but not appreciably or detectably expressed in normal colon cells.

3. Diskette 2 – Filename = Colon-3.txt – sequences and accession numbers listed in Figure 1 of U.S. Provisional Application 60/236,891 (filed 29 September 2000). There are 315 sequences (corresponding to SEQ ID NO: 523-837, respectively) contained in this listing, which represent genes found by Applicant to be down regulated by at least 2.09 fold in adenocarcinoma, here colon.

4. Diskette 2 – Filename = Colon-4.txt – sequences and accession numbers listed in Figure 1 of U.S. Provisional Application 60/236,842 (filed 29 September 2000). There are 230 (corresponding to SEQ ID NO: 838-1067, respectively) sequences contained in this listing, which represent genes found by Applicant to be up-regulated by at least 2.1 fold in adenocarcinoma, here colon.

All files are in text code (ASCII files) to facilitate searching.

It should be noted that most of the references cited in the accompanying Form 1449 and IDS (except for references G1, H1 and M1) were published after the Applicants' claimed priority date and are thus not considered by Applicants as representing prior art but are submitted to illustrate the efforts currently being made in this field.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

EXPRESS MAIL CERTIFICATE

Express Mail Label No. EL146097958US

Deposit Date: 2 May 2002

I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above addressed to:

**BOX SEQUENCE
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202**

 5/02/02
Alan J. Grant, Esq. Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389
CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
6 Becker Farm Road
Roseland, NJ 07068
Tel. No.: (973) 994-1700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 08 2002

TECH CENTER 1600/2900

APPLICATION OF: Young, et al.

SERIAL NO: 09/873,367

FILED: June 5, 2001

TITLE FOR: Cancer Gene Determination and Therapeutic Screening Using Signature Gene Sets

DOCKET NO: 689290-64



Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. In addition, a supplemental disclosure statement has been filed citing related copending applications.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

 §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

 The statement as specified in 37 CFR §1.97(e) set out below; OR

 The fee of \$ 180.00 under 37 CFR §1.17(p).

___§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).


___§1.97(e) The undersigned Attorney hereby states that:

___ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

___ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

<p>FIRST CLASS CERTIFICATE</p> <p>I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents Washington, D.C. 20231</p> <p>_____ Alan J. Grant, Esq. Date _____</p>	<p>Respectfully submitted,</p> <p></p> <p>Alan J. Grant, Esq. Reg. No. 33,389 CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN Six Becker Farm Road Roseland, NJ 07068 Tel: (973) 994-1700 Fax: (973) 994-1744</p>
---	---